{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:09:59Z","timestamp":1791155399432,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2005,8,25]],"date-time":"2005-08-25T00:00:00Z","timestamp":1124928000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1007\/s00280-005-0068-6","type":"journal-article","created":{"date-parts":[[2005,8,24]],"date-time":"2005-08-24T14:57:29Z","timestamp":1124895449000},"page":"685-692","source":"Crossref","is-referenced-by-count":189,"title":["Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics"],"prefix":"10.1007","volume":"57","author":[{"given":"Chetan","family":"Lathia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lettieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Cihon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Gallentine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Radtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavur","family":"Sundaresan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,8,25]]},"reference":[{"key":"68_CR1","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/dmd.31.7.815","volume":"31","author":"TD Bjornsson","year":"2003","unstructured":"Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S et\u00a0al (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815\u201332","journal-title":"Drug Metab Dispos"},{"key":"68_CR2","first-page":"47","volume":"2","author":"H Boxenbaum","year":"1999","unstructured":"Boxenbaum H (1999) Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of K i and dangers associated with high clearance drugs in general. J Pharm Pharm Sci 2:47\u201352","journal-title":"J Pharm Pharm Sci"},{"key":"68_CR3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S1533-0028(11)70463-7","volume":"3","author":"H DeGrendele","year":"2003","unstructured":"DeGrendele H (2003) Activity of the Raf kinase inhibitor BAY 43\u20139006 in patients with advanced solid tumors. Clin Colorectal Cancer 3:16\u201318","journal-title":"Clin Colorectal Cancer"},{"key":"68_CR4","unstructured":"Food and Drug Administration (FDA) (1999) Guidance for Industry entitled, \u201cIn vivo Drug metabolism\/Drug interaction studies\u2014study design, data analysis, and recommendations for dosing and labeling, US Department of Health and Human Services, Food and Drug Administration, Rockville, MD. Website: http:\/\/www.fda.gov\/cber\/gdlns\/metabol.pdf"},{"key":"68_CR5","first-page":"180","volume":"27","author":"MA Gibbs","year":"1999","unstructured":"Gibbs MA, Thummel KE, Shen DD, Kunze KL (1999) Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos 27:180\u2013187","journal-title":"Drug Metab Dispos"},{"key":"68_CR6","doi-asserted-by":"crossref","first-page":"616","DOI":"10.5414\/CPP41616","volume":"41","author":"M Heim","year":"2003","unstructured":"Heim M, Sharifi M, Hilger RA, Scheulen ME, Seeber S, Strumberg D (2003) Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006. Int J Clin Pharmacol Ther 41:616\u2013617","journal-title":"Int J Clin Pharmacol Ther"},{"key":"68_CR7","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.2174\/1381612023393053","volume":"8","author":"SJ Hotte","year":"2002","unstructured":"Hotte SJ, Hirte HW (2002) BAY 43-9006: early clinical data in patients with advanced solid malignancies. Curr Pharm Des 8:2249\u20132253","journal-title":"Curr Pharm Des"},{"key":"68_CR8","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0165-6147(99)01363-2","volume":"20","author":"M Ingelman-Sundberg","year":"1999","unstructured":"Ingelman-Sundberg M, Oscarson M, McLellan RA (1999) Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 20:342\u2013349","journal-title":"Trends Pharmacol Sci"},{"key":"68_CR9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1677\/erc.0.0080219","volume":"8","author":"JF Lyons","year":"2001","unstructured":"Lyons JF, Wilhelm S, Hibner B, Bollag G (2001) Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 8:219\u2013225","journal-title":"Endocr Relat Cancer"},{"key":"68_CR10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/clpt.1994.60","volume":"55","author":"KT Olkkola","year":"1994","unstructured":"Olkkola KT, Backman JT, Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55:481\u2013485","journal-title":"Clin Pharmacol Ther"},{"key":"68_CR11","doi-asserted-by":"crossref","first-page":"620","DOI":"10.5414\/CPP41620","volume":"41","author":"H Richly","year":"2003","unstructured":"Richly H, Kupsch P, Passage K, Grubert M, Hilger RA, Kredtke S et\u00a0al (2003) A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors. Int J Clin Pharmacol Ther 41:620\u2013621","journal-title":"Int J Clin Pharmacol Ther"},{"key":"68_CR12","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1177\/00912700122010212","volume":"41","author":"AD Rodrigues","year":"2001","unstructured":"Rodrigues AD, Winchell GA, Dobrinska MR (2001) Use of in vitro drug metabolism data to evaluate metabolic drug-drug interactions in man: the need for quantitative databases. J Clin Pharmacol 41:368\u2013373","journal-title":"J Clin Pharmacol"},{"key":"68_CR13","doi-asserted-by":"crossref","first-page":"580","DOI":"10.5414\/CPP40580","volume":"40","author":"D Strumberg","year":"2002","unstructured":"Strumberg D, Voliotis D, Moeller JG, Hilger RA, Richly H, Kredtke S et\u00a0al (2002) Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther 40:580\u2013581","journal-title":"Int J Clin Pharmacol Ther"},{"key":"68_CR14","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","volume":"23","author":"D Strumberg","year":"2005","unstructured":"Strumberg D, Richly H, Hilger RA, Scheuler N, Korfee S, Tewes M et\u00a0al (2005) Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965\u2013972","journal-title":"J Clin Oncol"},{"key":"68_CR15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200038020-00002","volume":"38","author":"K Venkatakrishnan","year":"2000","unstructured":"Venkatakrishnan K, von Moltke LL, Greenblatt DJ (2000) Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 38:111\u2013180","journal-title":"Clin Pharmacokinet"},{"key":"68_CR16","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1124\/dmd.30.3.314","volume":"30","author":"W Zhang","year":"2002","unstructured":"Zhang W, Ramamoorthy Y, Kilicarslan T, Nolte H, Tyndale RF, Sellers EM (2002) Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab Dispos 30:314\u2013318","journal-title":"Drug Metab Dispos"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-005-0068-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-005-0068-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-005-0068-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:06:14Z","timestamp":1559037974000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-005-0068-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,25]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["68"],"URL":"https:\/\/doi.org\/10.1007\/s00280-005-0068-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,25]]}}}